The Discovery of Natural Products with Therapeutic Potential

Edited by

Vincent P. Gullo
Schering-Plough Research Institute
Kenilworth, New Jersey
# CONTENTS

**Preface**  

**PART I. THE SOURCE OF CHEMICAL DIVERSITY**

1. **Aerobic Actinomycetes: A Continuing Source of Novel Natural Products**  
   Ann C. Horan  
   1.1 Micromonosporae  
   1.2 Non-Micromonosporae–Non-Streptomycetes  
   1.3 Nocardioform Actinomycetes  
   1.4 Conclusions  
   References  
   3  
   5  
   8  
   18  
   25  
   27

2. **Bacteria As a Source of Novel Therapeutics**  
   J.C. Hunter-Cevera and Angela Belt  
   2.1 Sources of Bacteria for Screens  
   2.2 Methods for Isolating Bacteria  
   2.3 Sample Processing  
   2.4 Subculturing and Purification  
   31  
   32  
   37  
   40  
   44
PART II. NEW TARGETS FOR SCREENING ASSAYS

6. Mechanism-Based Screening for the Discovery of Novel Antifungals

Donald R. Kirsch and Beth J. DiDomenico

6.1 General Strategies for the Discovery of Antifungal Agents

6.2 Overview of Design Strategies for Mechanism-of-Action-Based Screens

6.3 Screening Approaches for Antifungals Acting on Cell Wall Biosynthesis

6.4 Screening Approaches for Antifungals Acting on Ergosterol Biosynthesis

6.5 Screening Approaches for Antifungals Acting on the Cytoskeleton

6.6 Screening Approaches for Antifungals Acting on Other Targets

6.7 Closing Comments

References

7. Strategies for Discovering Antiviral Agents from Natural Products

E. Rozhon, R. Albin, and J. Schwartz

7.1 Antiviral Therapy: A Historical Perspective

7.2 Antiviral Research Today: A Combination of Classical Virology and Molecular Biology

7.3 Testing Naturally Derived Samples for Antiviral Activity: Advantages and Disadvantages

7.4 Strategies for Identifying Specific Antiviral Activities in Natural Products

7.5 Examples of New Technologies for Optimizing Antiviral Activity and Predicting the Effect of Antiviral Agents Prior to Clinical Studies

7.6 Conclusion

References

8. Mechanism-Based Screens in the Discovery of Chemotherapeutic Antibacterials

Sunil Kadam

8.1 Historical Perspective

8.2 Antibacterials and Emerging Targets

8.3 Summary

References
## Contents

### 9. Oncogene Function Inhibitors of Microbial Origin

*Kazuo Umezawa*

- 9.1 Tyrosine Kinase Inhibitors
- 9.2 Inhibitors of ras Oncogene Functions
- 9.3 Inhibitors of Phosphatidylinositol Turnover
- 9.4 Future Directions

References

### 10. Screening Methodologies for the Discovery of Novel Cytotoxic Antitumor Agents

*Anna M. Casazza and Byron H. Long*

- 10.1 In Vitro Biochemical Assays
- 10.2 Mammalian Cell-Based Assays
- 10.3 In Vivo Animal Models
- 10.4 Conclusions

References

### 11. Hypcholesterolemic Agents

*Akira Endo*

- 11.1 Background of Approach
- 11.2 Assay of Cholesterol Biosynthesis
- 11.3 Compactin-Related Compounds
- 11.4 Other Inhibitors of Cholesterol Biosynthesis

References

### 12. Immunomodulators

*Masakuni Okuhara and Toru Kino*

- 12.1 Screening for Immunosuppressants
- 12.2 Screening for Immunostimulants
- 12.3 Perspectives: New Targets for Immunomodulators

References

## PART III. ISOLATION AND STRUCTURE DETERMINATION OF NATURAL PRODUCTS

### 13. Isolation and Purification of Secondary Metabolites

*James B. McAlpine and Jill E. Hochlowski*

- 13.1 Partition Chromatography
- 13.2 Adsorption Chromatography
- 13.3 Size Exclusion Chromatography
- 13.4 Reversed Phase Chromatography
- 13.5 Ion Exchange Chromatography
- 13.6 Affinity Chromatography
- 13.7 Conclusions

References
14. **Modern Spectroscopic Approaches to Structure Elucidation** 389
   Otto D. Hensens
   14.1 Structure Elucidation Process: Part A 391
   14.2 Structure Elucidation Process: Part B 405
   14.3 Conclusion and Future Trends 428
   References 433

*Index* 445